Shots:

• The approval was based on the P-III (EXPLORER-HCM) trial to evaluate Camzyos vs PBO in a ratio (1:1) in 251 adult patients with NYHA class II-III obstructive HCM to improve functional capacity & symptoms
• The results showed that 37% vs 17% of patients achieved the composite 1EPs @30wk., greater improvement across all 2EPs including mean change from baseline post-exercise LVOT peak gradient & pVO2, improvement of NYHA class ≥1 (65% vs 31%)
• Mean change from baseline in KCCQ-23 † CSS, KCCQ-23 TSS & KCCQ-23 PL, mean resting LVEF was 74% at baseline in both groups, 6% vs 2% experienced reversible reductions in LVEF to <50%. The company offers multiple programs and resources along with patients support

Ref: Businesswire | Image: Bristol Myers Squibb